Category: COVID-19

Why We’re Pledging #NoGoingBack for Clinical Trials


The #NoGoingBack pledge is a statement from organisations across the world to continue forging forward. It’s a united front, and shows the importance of clinical leaders coming together to continue the momentum we’ve created in improving clinical trial conduct around the world.

Clinical Trial Continuity During The Ongoing COVID-19 Pandemic


The clinical trial landscape has changed dramatically since the outbreak of COVID-19. For the clinical research industry, these past few months have been anything but business as usual. However, it hasn’t meant clinical trials can’t continue, and many in the industry have been working together to find a ‘new normal’.

COVID-19 Pandemic: What Lessons Can We Learn to Put Patients First in Clinical Trial Design


The COVID-19 pandemic has forced quick thinking and adaptation in clinical trials to ensure patient safety and, where possible, continue research and preserve study integrity. Changes have impacted protocols, use of technologies, data collection, and how patients are participating in trials. On June 11, we hosted the first of a series of mdWebinars to facilitate […]